Highlights

  • Sonic Healthcare reported FY26 underlying Revenue of AUD 10.9 billion, with EBITDA growing approximately 11% and Earnings Per Share growing approximately 17% year on year.
  • FY27 EBITDA guidance of AUD 1,950 to AUD 2,030 million (constant currency, excluding IT transformation costs) has been reaffirmed after four months of trading, with organic revenue growth year to date at approximately 4.4% per working day.
  • The Federation 2.0 initiative aims to capture greater financial value from the company's federated structure through lower structural costs and sharing innovation across markets.
  • A global digital and AI transformation programme is underway, with approximately AUD 30 million per year committed for three years to modernise finance, Supply chain, and HR systems.

Sonic Healthcare Limited (ASX:SHL) presented its 2026 Annual General Meeting update, providing shareholders with a review of FY26 financial performance and an outlook for FY27. Sonic Healthcare is one of the world's leading medical diagnostics companies, operating pathology, radiology, and clinical services businesses across nine countries through 343 laboratories and more than 3,200 patient access points. The company is number one in six of its markets and conducted approximately 144 million patient consultations in FY26.

FY26 Financial Performance

FY26 underlying revenue reached approximately AUD 10.9 billion, representing 13% year-on-year growth. EBITDA grew approximately 11%, and net profit grew approximately 14%. Earnings per share increased approximately 17%, reaching 125.6 cents. Return on invested Capital improved by approximately 60 basis points to 6.5%. Organic revenue growth for the year was approximately 5%. The company declared total dividends of AUD 1.08 per share for FY26, representing a 0.9% increase over the prior year. Dividends are franked to 60%.

Key operational highlights included advanced Acquisition synergy realisation from the LADR acquisition in Germany (more than 40% of total expected synergies achieved in the first year) and the Synlab Suisse and Dr Risch Group integration in Switzerland. Advanced diagnostics — including Sonic Genetics in Australia, Biovis in Germany, and the US division including Cairo Diagnostics — delivered double-digit organic growth. Direct-to-consumer testing through Mein Direktlabor in Germany grew by over 60%. A US operating review delivered cost reductions including rationalisation of nine anatomical pathology practices and a 10% reduction in support function headcount.

Federation 2.0 and Digital Transformation

The company is pursuing a Federation 2.0 strategy aimed at extracting greater financial value from its federated operating model while preserving its local brand, customer relationship, and entrepreneurship advantages. The strategy focuses on two financial value levers: a lower structural cost base through increasing scale efficiencies and reducing duplication across the federation, and improved revenue growth through sharing innovation, proven strategies, and digital infrastructure enterprise-wide. In Germany, eleven federation member businesses have been combined into three operating divisions to accelerate synergy capture.

The global digital and AI transformation programme, launched in FY26, involves approximately AUD 30 million per year for three years to modernise back-office finance, supply chain, and HR systems, while also optimising laboratory and radiology workflows and scaling digital and AI clinical applications. New global Leadership roles have been created, including a Chief Digital, Data and Information Officer. The company describes this Investment as building a foundation for responsible AI use across its operations while improving productivity and reducing duplication.

FY27 Guidance and Strategic Growth Priorities

FY27 EBITDA guidance of AUD 1,950 to AUD 2,030 million on a constant-currency basis (excluding back-office IT transformation costs of approximately AUD 30 million) was reaffirmed after four months of trading. Organic revenue growth year to date to October 2026 was approximately 4.4% per working day, in line with expectations. Strong organic growth rates were maintained across Germany, Australian pathology, the United States, the United Kingdom, and radiology. Interest expense is expected to increase by approximately 8% versus the prior year due to Base Rate rises.

Strategic growth priorities for the medium term include expanding personalised and precision medicine in key areas such as women's health, neurology, mental health, and longevity testing, broadening customer access through digital channels, scaling automation and AI to grow capacity and reduce cost, and optimising the federation to capture more value from global scale. The company has also signed a new conditional contract to provide pathology services to Mater hospitals in Brisbane, adding a new major institutional client.

Key Insights

Sonic Healthcare's consistent track record of approximately 5% organic growth across diverse geographic markets, combined with ongoing acquisition integration, provides a relatively predictable near-term earnings growth profile that supports the reaffirmed FY27 guidance.

The Federation 2.0 initiative represents a structural change in how Sonic Healthcare manages its operating model, with the consolidation of German operations being the most visible early manifestation and a template for potential application across other markets.

The AUD 90 million, three-year digital transformation investment is a meaningful commitment relative to annual EBITDA, underscoring management's view that modernising back-office and clinical systems is a prerequisite for sustaining competitive margins at scale.